Hypofractionated Intensity-Modulated Radiotherapy for Carcinoma of the Prostate: Analysis of Toxicity
- 15 July 2009
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 74 (4) , 1121-1127
- https://doi.org/10.1016/j.ijrobp.2008.09.032
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- In Reply to Drs. Schulz and KaganInternational Journal of Radiation Oncology*Biology*Physics, 2008
- The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397)Radiotherapy and Oncology, 2007
- Radiation dose and late failures in prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysisInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Scoring of treatment-related late effects in prostate cancerRadiotherapy and Oncology, 2002
- Dose response in prostate cancer with 8–12 years’ follow-upInternational Journal of Radiation Oncology*Biology*Physics, 2002
- High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patientsInternational Journal of Radiation Oncology*Biology*Physics, 2002
- Hypofractionation for prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 2001
- Importance of high radiation doses (72 Gy or greater) in the treatment of Stage T1-T3 adenocarcinoma of the prostateUrology, 2000